Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP: 1.Intro and Welcomes

EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

Now Viewing

EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP: 9.Advanced Treatment Options for RA: Exploring the Data

EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity

EP: 13.Outcomes of Class Switching vs Cycling TNF Inhibitors

EP: 14.Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

EP: 15.Safety and Efficacy of Janus Kinase Inhibitors

EP: 16.Closing Remarks

Video content above is prompted by the following:

Conventional synthetic disease-modifying antirheumatic drugs (csDMARDS), including methotrexate, are generally considered first-line treatment.The American College of Rheumatology (ACR) Guidelines recommend monitoring disease activity at least every 3 months, based on the safety and efficacy of the chosen therapy, and adjusting therapy as needed in the absence of improvement. For patients with ongoing active disease or with poor prognostic factors, combination DMARD therapy or advanced treatment with a biologic agent is typically initiated.

In your practice, how do you assess rheumatoid arthritis disease activity and therapeutic response?